During the past decade, Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 10 clinical trials were completed, i.e. on average, 29.4% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 5 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 36 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 8 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored, "Gruppo Italiano Trapianto di Midollo Osseo" with 3 trials sponsored and "Northern Italy Leukemia Group" with 3 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Associazione Italiana per la Ricerca sul Cancro" with 1 trials as a collaborator, "CML Advocates Network" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator and "European Leukemia Net" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" are "Chronic Myeloid Leukemia" (11 trials), "Chronic Lymphocytic Leukemia" (7 trials), "Acute Myeloid Leukemia" (5 trials), "Non-Hodgkin's Lymphoma" (5 trials) and "Acute Lymphoblastic Leukemia" (4 trials). Many other conditions were trialed in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" in a lesser frequency.

Most popular intervention types in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" are "Drug" (42 trials), "Other" (8 trials), "Behavioral" (2 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bendamustine" (5 trials), "Rituximab" (5 trials), "Cyclophosphamide" (4 trials), "Venetoclax" (4 trials) and "Obinutuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora" are 62 trials for "All" genders.

Currently, there are 23 active trials in "Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora". 1 are not yet recruiting, 12 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora, 3 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".